Epigenomics last week said it obtained a non-exclusive license from Affymetrix to access its microarray technology to develop array-based in vitro diagnostics for oncology.

The Berlin-based company can now transfer its diagnostic and prognostic tests for prostate and breast cancer • its first products for the molecular diagnostic market • onto Affy's platform to use in clinical trials so the US Food and Drug Administration can begin reviewing them sometime next year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.